Axl - Axl receptor tyrosine kinase Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 308444

Summary

Enables Myosin heavy chain binding activity and phosphatidylinositol 3-kinase binding activity. Involved in several processes, including animal organ regeneration; cellular response to hydrogen peroxide; and negative regulation of apoptotic process. Predicted to be located in several cellular components, including actin cytoskeleton; cell surface; and host cell surface. Predicted to be part of receptor complex. Predicted to be integral component of plasma membrane. Used to study glomerulonephritis. Human ortholog(s) of this gene implicated in type 2 diabetes mellitus. Orthologous to human Axl (Axl receptor tyrosine kinase). [provided by Alliance of Genome Resources, Apr 2022]

Axl Products (2)

mRNA Protein Name
NM_001013147.2 NP_001013165.2 tyrosine-protein kinase receptor UFO isoform 2 precursor
NM_031794.2 NP_113982.2 tyrosine-protein kinase receptor UFO isoform 1 precursor

Gene Ontology

  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence References Source
enables myosin heavy chain binding IPI
IPI: Inferred from physical interaction
20479336 RGD
enables phosphatidylinositol 3-kinase binding IPI
IPI: Inferred from physical interaction
18292389 RGD
Biological Process GO Annotation Evidence References Source
involved in animal organ regeneration IEP
IEP: Inferred from expression pattern
16285961 RGD
involved in cell differentiation IMP
IMP: Inferred from mutant phenotype
20479336 RGD
involved in cellular response to hydrogen peroxide IDA
IDA: Inferred from direct assay
20479336 RGD
involved in negative regulation of apoptotic process IMP
IMP: Inferred from mutant phenotype
15380678 RGD
involved in response to axon injury IEP
IEP: Inferred from expression pattern
20187850 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

tyrosine-protein kinase receptor UFO

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (4)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-13016 Cabozantinib Inhibitor 99.97% Yes
HY-12432 Gilteritinib Inhibitor 99.84% Yes
HY-12432A Gilteritinib hemifumarate Inhibitor 99.75% Yes
HY-13016A Cabozantinib hydrochloride Inhibitor / Unkown

Clinical Phase

Bioactive Molecules (10)
Cat. No. Product Name Effect
Purity Phase
HY-15150 Bemcentinib Inhibitor 99.92% Phase 3
HY-138696 Zanzalintinib Inhibitor 99.91% Phase 3
HY-12076 BMS 777607 Inhibitor 99.36% Phase 2
HY-12963 Dubermatinib Inhibitor 99.47% Phase 2
HY-114358 Tamnorzatinib Inhibitor 98.59% Phase 2
HY-107145A Ningetinib Inhibitor 99.63% Phase 2
HY-15150G Bemcentinib (GMP) Inhibitor / Phase 2
HY-100946 CEP-40783 Inhibitor 99.61% Phase 1
HY-147218 PF-07265807 Inhibitor 95.18% Phase 1
HY-176205 Ligritinib Inhibitor 98.08% Phase 1
Inhibitory Antibodies (4)
Cat. No. Product Name Effect
Purity Phase
HY-P99463 Batiraxcept 99.91% Phase 3
HY-P99360 Enapotamab Inhibitor 99.9% Phase 2
HY-P99161 Tilvestamab Inhibitor 98.08% Phase 1
HY-P991664 AG01 Inhibitor 95.10% Phase 1

Pre-clinical Phase

Bioactive Molecules (47)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-114166 2-D08 Inhibitor 99.37% Unkown
HY-15797 UNC2250 Inhibitor 99.92% Unkown
HY-12494 LDC1267 Inhibitor 99.64% Unkown
HY-117596 UNC569 Inhibitor 99.92% Unkown
HY-132200 UNC5293 Inhibitor 99.93% Unkown
HY-12964 SGI-7079 Inhibitor 99.32% Unkown
HY-173268 UNC9426 Inhibitor 99.51% Unkown
HY-100509 NPS-1034 Inhibitor 98.0% Unkown
HY-117548 UNC1062 Inhibitor 98.92% Unkown
HY-124066 RU-302 Inhibitor 98.72% Unkown
HY-15798 UNC2881 Inhibitor 98.29% Unkown
HY-124502 UNC4203 Inhibitor 99.80% Unkown
HY-152830 Adrixetinib Inhibitor 99.55% Unkown
HY-114357A DS-1205b free base Inhibitor 99.92% Unkown
HY-132893 AZ14145845 Inhibitor 98.00% Unkown
HY-107145 Ningetinib Tosylate Inhibitor 99.59% Unkown
HY-144627 PROTAC Axl Degrader 2 Inhibitor 96.07% Unkown
HY-13016S Cabozantinib-d6 Inhibitor 98.14% Unkown
HY-151904 AXL-IN-13 Inhibitor 98.03% Unkown
HY-152830A Adrixetinib TFA Inhibitor 99.82% Unkown
HY-150041 TL4830031 Inhibitor ≥98.0% Unkown
HY-146615 Axl-IN-6 Inhibitor / Unkown
HY-153441 AXL-IN-15 Inhibitor / Unkown
HY-104075 R916562 Inhibitor / Unkown
HY-149092 Anticancer agent 109 / Unkown
HY-147577 Axl-IN-10 Inhibitor / Unkown
HY-147579 Axl-IN-12 Inhibitor / Unkown
HY-144706 Axl-IN-3 Inhibitor / Unkown
HY-162085 Axl-IN-17 Inhibitor / Unkown
HY-122601 TAM-IN-1 Inhibitor / Unkown
HY-N12041 Axl-IN-16 Inhibitor / Unkown
HY-179535 Axl-IN-21 Inhibitor / Unkown
HY-146596 Axl-IN-5 Inhibitor / Unkown
HY-149491 HIV-IN-7 Inhibitor / Unkown
HY-147576 Axl-IN-9 Inhibitor / Unkown
HY-147574 Axl-IN-7 Inhibitor / Unkown
HY-152075 AXL-IN-14 Inhibitor / Unkown
HY-184184 Axl ligand-1 Ligand / Unkown
HY-173400 UNC8212 Inhibitor / Unkown
HY-147575 Axl-IN-8 Inhibitor / Unkown
HY-144708 Axl-IN-4 Inhibitor / Unkown
HY-144624 PROTAC Axl Degrader 1 Degrader / Unkown
HY-115778 UNC3133 Inhibitor / Unkown
HY-147578 Axl-IN-11 Inhibitor / Unkown
HY-176204 Axl-IN-19 Inhibitor / Unkown
HY-183774 NTQ2494 Inhibitor / Unkown
HY-153012 Axl/Mer/CSF1R-IN-1 Inhibitor / Unkown
Inhibitory Antibodies (3)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P9988 Mecbotamab Inhibitor 99.83% Unkown
HY-P99733 Mipasetamab Inhibitor 98.26% Unkown
HY-P992116 Ladarutatug Inhibitor 95.40% Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Axl NCBI NCBI:558